Results 201 to 210 of about 10,468 (295)

The Development of Anti-Tumor Activity of Sulfonylurea Compounds

Hans Journal of Medicinal Chemistry, 2015
openaire   +1 more source

Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk: A Randomized Clinical Trial.

JAMA Netw Open
Gilliam LK, Parker MM, Chen MW, Karter AJ, Grant RW.   +4 more
europepmc   +1 more source

Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study. [PDF]

Clin Mol Hepatol
Jang H, Kim Y, Lim YK, Lee DH, Joo SK, Koo BK, Kim GA, Lee W, Romeo S, Kim W, Innovative Target Exploration of NAFLD (ITEN) consortium.   +10 more
europepmc   +1 more source

Impact of renal function on antidiabetic drug selection in Japan: A real‐world analysis using the J‐DREAMS database

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 801-809, May 2026.
Using a large Japanese real‐world database, we examined antidiabetic drug selection in first and second therapy stratified by renal function and study period. The earlier initiation of SGLT2 inhibitors and GLP‐1 receptor agonists increased over time, particularly in second therapy, with prescribing patterns increasingly aligned across renal function ...
Masashi Kubota, Mitsuru Ohsugi, Kohjiro Ueki   +2 more
wiley   +1 more source

Binding of sulfonylurea-related compounds with bovine serum albumin.

Chemical and Pharmaceutical Bulletin, 1978
S, Goto, H, Yoshitomi, M, Nakase
openaire   +2 more sources

Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

Ann Med
Gao M, Lin Q, Hu K, Zhong B, Zhu T, Gong Z, Zhang K, Chen X, Chen X, Zhang Y, Li Y, Tang S, Su D, Liang X, Liu Y.   +14 more
europepmc   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 766-780, May 2026.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu, Ying Chun Lee, Yu‐Wei Fang, Wen‐Hui Hsieh, Ming‐Hsien Tsai   +4 more
wiley   +1 more source

Real-World Harm Reduction of Metformin Plus DPP4 Inhibitors versus Metformin Plus Sulfonylureas in Older Adults: A Target Trial Emulation Using German Claims Data. [PDF]

Drugs Aging
Starke P, Thürmann P, Grobe T, Friede T, Mathes T.   +4 more
europepmc   +1 more source

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

Plant Biotechnology Journal, Volume 24, Issue 5, Page 3158-3171, May 2026.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Influence of test conditions and exposure duration on the result of ecotoxicological tests:Consequences for derivation of environmental quality standards [PDF]

, 2013
Rosenkrantz, Rikke Tjørnhøj
core